Industry experts are grappling with the challenge of how to prioritize investment in vaccine development for future pandemic risks while also incentivizing development of vaccines for existing health problems like neglected tropical diseases. “One of the big issues is how do you balance the needs of pandemic threats . . . . and chronic and debilitating neglected diseases that are clearly a problem,” Peter Hotez, director of the Center for Global Health and Diseases at Baylor College of Medicine, said...